Evidence / Nankivell et al. · 2026
Ubiquinol and cognitive measures in older adults
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, placebo-controlled human trial.
- Product relevance
- Ingredient evidence for reduced CoQ10.
- Sample or population
- 111 adults aged 60 or older, with 61 assigned to ubiquinol and 50 to placebo.
- Studied dose
- The abstract reports 200 mg of ubiquinol and does not specify dosing frequency.
- Duration
- 90 days.
- Finding
- Plasma CoQ10 was higher with ubiquinol. Adjusted between-group analyses showed no differences in cognition, cardiovascular measures, mood or the reported inflammation and oxidative-stress markers.
- Limitations
- The within-group correlations do not overturn the null between-group findings.
- Study quality
- Randomized comparison with adjusted analyses and exploratory regressions. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.